Agency Information Collection Activities: Submission to OMB for Review and Approval; Public Comment Request, 79347-79348 [2015-31936]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by February 2, 2016.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with disabilities.
If you require accommodations due to a
disability, please contact Lee L.
Zwanziger at least 7 days in advance of
the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: December 15, 2015.
Jill Hartzler Warner,
Associate Commissioner for Special Medical
Programs.
[FR Doc. 2015–31893 Filed 12–18–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Health Resources and Services
Administration
Agency Information Collection
Activities: Submission to OMB for
Review and Approval; Public Comment
Request
Health Resources and Services
Administration, HHS.
ACTION: Notice.
AGENCY:
In compliance with Section
3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health
Resources and Services Administration
(HRSA) has submitted an Information
Collection Request (ICR) to the Office of
Management and Budget (OMB) for
review and approval. Comments
submitted during the first public review
of this ICR will be provided to OMB.
OMB will accept further comments from
the public during the review and
approval period.
DATES: Comments on this ICR should be
received no later than January 20, 2016.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:38 Dec 18, 2015
Jkt 238001
Submit your comments,
including the Information Collection
Request Title, to the desk officer for
HRSA, either by email to OIRA_
submission@omb.eop.gov or by fax to
202–395–5806.
FOR FURTHER INFORMATION CONTACT: To
request a copy of the clearance requests
submitted to OMB for review, email the
HRSA Information Collection Clearance
Officer at paperwork@hrsa.gov or call
(301) 594–4306.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title:
The Maternal, Infant, and Early
Childhood Home Visiting Program
Performance Measurement Information
System.
OMB No.: 0906–xxxx—NEW.
Abstract: The Maternal, Infant, and
Early Childhood Home Visiting Program
(MIECHV), administered by HRSA in
partnership with the Administration for
Children and Families (ACF), supports
voluntary, evidence-based home visiting
services during pregnancy and to
parents with young children up to
kindergarten entry. States and territories
(as well as nonprofit organizations
selected to provide services in nonparticipating states and territories) are
eligible to receive funding from the
Home Visiting Program and have
flexibility to tailor the program to serve
the specific needs of their communities.
Need and Proposed Use of the
Information: HRSA will use the
proposed information to demonstrate
program accountability and
continuously monitor and provide
oversight to state and territory Home
Visiting Program grantees. The
information will also be used to provide
quality improvement guidance and
technical assistance to grantees and help
inform the development of early
childhood systems at the national, state,
and local level. HRSA is seeking to
collect demographic, service utilization,
and select clinical indicators for
participants enrolled in home visiting
services. In addition, HRSA will collect
a set of standardized performance and
system outcome indicators that
correspond with the statutorily
identified benchmark areas.
Demographic, Service Utilization, and
Clinical Indicators Data: These data will
describe the population served by the
Home Visiting Program, including the
unduplicated count of the number of
participants and participant groups by
race and ethnicity. These data will
provide other socio-demographic
ADDRESSES:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
79347
characteristics of program participants
and their utilization of services, such as
program retention. Additionally, these
data will describe several select clinical
indicators of program participants, such
as a child’s usual source of medical
care. This information will be collected
from participants at enrollment in home
visiting services and aggregated and
reported to HRSA by state/territory
grantees once annually.
Performance and System Outcome
Benchmark Data: These data constitute
a discrete set of standardized
performance and system outcome
indicators that correspond with the
statutorily identified benchmark areas.
These data will provide aggregate totals,
percentages, and rates for performance
and system outcome indicators that are
salient to the Home Visiting Program,
home visiting services more generally,
and the at-risk populations served.
These data will be collected from
participants based on the appropriate
measurement period defined for each
measure and aggregated and reported to
HRSA by state/territory grantees once
annually.
This information will be used to
demonstrate accountability with
legislative and programmatic
requirements. It will also be used to
monitor and provide continued
oversight for grantee performance and to
target technical assistance resources to
grantees. In the future, it is anticipated
that Home Visiting Program funding
decisions may be allocated based on
grantee performance, including on
benchmark performance areas.
Likely Respondents: Home Visiting
Program grantees.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this ICR are
summarized in the table below.
E:\FR\FM\21DEN1.SGM
21DEN1
79348
Federal Register / Vol. 80, No. 244 / Monday, December 21, 2015 / Notices
TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS
Number of
respondents
Form name
Number of
responses per
respondent
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
Form 1: Demographic, Service Utilization, and Clinical Indicators Data ....................................................................
Form 2: Performance and System Outcome Benchmark
Data ..................................................................................
56
1
56
425
23,800
56
1
56
425
23,800
Total ..............................................................................
56
........................
56
........................
47,600
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015–31936 Filed 12–18–15; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by emailing the
indicated licensing contact at the
National Heart, Lung, and Blood, Office
of Technology Transfer and
Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
Fluorescent Nanodiamonds as Fiducial
Markers for Microscopy
Description of Technology
The invention relates to fluorescent
nanodiamonds (FNDs) and their uses as
fiducial markers for microscopy. FNDs
are bright fluorescent probes that do not
blink or bleach and have broad
VerDate Sep<11>2014
17:38 Dec 18, 2015
Jkt 238001
fluorescence excitation and emission
peaks. The fluorescence intensity can be
readily controlled by the size of the
FND, the number of fluorescent centers
produced in the nanodiamonds, or in
situ through the application of a weak
magnetic field. The particular advantage
of the FND compositions of this
invention are that they are particularly
useful for extended imaging of a single
sample over time periods that can be as
long as a week or more. In an exemplary
embodiment, FNDs are immobilized in
a substrate that are coated with an inert
top coating, like silicon dioxide, or
transparent polymer (e.g. poly-L-lysine,
poly-L-arginine, or siloxanes).
Generally, any suitable methods known
for surface functionalization of the
substrate can be used to make the
composition. In another aspect of this
invention, the inventors designed
software for super-resolution imaging
correction method is employed to
precisely determine the position
coordinates of each of a set of FNDs in
a plurality of images by using Gaussian
fitting of the point spread function
comprises each of the FNDs in the
plurality of images. The calculated
correction is then used to displace each
image to align the coordinates of the
FNDs. The positions of the FNDs can be
tracked with sub-nanometer precision
and residual drift can be reduced to the
nanometer scale over hundreds of hours
of tracking.
Potential Commercial Applications
• Fluorescent Microscopy
• Super-resolution microscopy
• Correlative imaging techniques
combing fluorescence microscopy
with electron, x-ray, or atomic force
microscopy imaging modalities
Competitive Advantages
•
•
•
•
•
Non-blinking, Non-bleaching
Chemically inert
Chemically and physically stable
Broad excitation
Longevity
Development Stage
• In vitro data
PO 00000
Frm 00047
Fmt 4703
Sfmt 4703
Inventors
• Keir Neuman, Ambika Bumb, Han
Wen, Jennifer Hong and Susanta
Sarkar (all of NHLBI)
• Chang Yi, Lawrence Samelson, Asit
Manna (all of NCI)
Intellectual Property: HHS Reference
No. E–217–2015/0–US–01
• US Provisional Patent Application 62/
262,058 filed December 2, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Heart, Lung and Blood
Institute seeks statements of capability
or interest from parties interested in
collaborative research to further develop
and evaluate metallic nanoparticle
vesicles for cancer phototherapy. For
collaboration opportunities, please
contact Vincent Kolesnitchenko, Ph.D.
at kolesniv@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2015–31890 Filed 12–18–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Submission for OMB Review; 30-Day
Comment Request; Generic Clearance
for the Collection of Qualitative
Feedback on Agency Service Delivery
(NIAID)
Under the provisions of
Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the National
Institutes of Health, has submitted to the
Office of Management and Budget
(OMB) a request for review and
approval of the information collection
listed below. This proposed information
collection was previously published in
the Federal Register on October 1, 2015,
80 FR 59168 and allowed 60-days for
SUMMARY:
E:\FR\FM\21DEN1.SGM
21DEN1
]]>Agencies
[Federal Register Volume 80, Number 244 (Monday, December 21, 2015)]
[Notices]
[Pages 79347-79348]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-31936]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Health Resources and Services Administration
Agency Information Collection Activities: Submission to OMB for
Review and Approval; Public Comment Request
AGENCY: Health Resources and Services Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: In compliance with Section 3507(a)(1)(D) of the Paperwork
Reduction Act of 1995, the Health Resources and Services Administration
(HRSA) has submitted an Information Collection Request (ICR) to the
Office of Management and Budget (OMB) for review and approval. Comments
submitted during the first public review of this ICR will be provided
to OMB. OMB will accept further comments from the public during the
review and approval period.
DATES: Comments on this ICR should be received no later than January
20, 2016.
ADDRESSES: Submit your comments, including the Information Collection
Request Title, to the desk officer for HRSA, either by email to
OIRA_submission@omb.eop.gov or by fax to 202-395-5806.
FOR FURTHER INFORMATION CONTACT: To request a copy of the clearance
requests submitted to OMB for review, email the HRSA Information
Collection Clearance Officer at paperwork@hrsa.gov or call (301) 594-
4306.
SUPPLEMENTARY INFORMATION:
Information Collection Request Title: The Maternal, Infant, and
Early Childhood Home Visiting Program Performance Measurement
Information System.
OMB No.: 0906-xxxx--NEW.
Abstract: The Maternal, Infant, and Early Childhood Home Visiting
Program (MIECHV), administered by HRSA in partnership with the
Administration for Children and Families (ACF), supports voluntary,
evidence-based home visiting services during pregnancy and to parents
with young children up to kindergarten entry. States and territories
(as well as nonprofit organizations selected to provide services in
non-participating states and territories) are eligible to receive
funding from the Home Visiting Program and have flexibility to tailor
the program to serve the specific needs of their communities.
Need and Proposed Use of the Information: HRSA will use the
proposed information to demonstrate program accountability and
continuously monitor and provide oversight to state and territory Home
Visiting Program grantees. The information will also be used to provide
quality improvement guidance and technical assistance to grantees and
help inform the development of early childhood systems at the national,
state, and local level. HRSA is seeking to collect demographic, service
utilization, and select clinical indicators for participants enrolled
in home visiting services. In addition, HRSA will collect a set of
standardized performance and system outcome indicators that correspond
with the statutorily identified benchmark areas.
Demographic, Service Utilization, and Clinical Indicators Data:
These data will describe the population served by the Home Visiting
Program, including the unduplicated count of the number of participants
and participant groups by race and ethnicity. These data will provide
other socio-demographic characteristics of program participants and
their utilization of services, such as program retention. Additionally,
these data will describe several select clinical indicators of program
participants, such as a child's usual source of medical care. This
information will be collected from participants at enrollment in home
visiting services and aggregated and reported to HRSA by state/
territory grantees once annually.
Performance and System Outcome Benchmark Data: These data
constitute a discrete set of standardized performance and system
outcome indicators that correspond with the statutorily identified
benchmark areas. These data will provide aggregate totals, percentages,
and rates for performance and system outcome indicators that are
salient to the Home Visiting Program, home visiting services more
generally, and the at-risk populations served. These data will be
collected from participants based on the appropriate measurement period
defined for each measure and aggregated and reported to HRSA by state/
territory grantees once annually.
This information will be used to demonstrate accountability with
legislative and programmatic requirements. It will also be used to
monitor and provide continued oversight for grantee performance and to
target technical assistance resources to grantees. In the future, it is
anticipated that Home Visiting Program funding decisions may be
allocated based on grantee performance, including on benchmark
performance areas.
Likely Respondents: Home Visiting Program grantees.
Burden Statement: Burden in this context means the time expended by
persons to generate, maintain, retain, disclose or provide the
information requested. This includes the time needed to review
instructions; to develop, acquire, install and utilize technology and
systems for the purpose of collecting, validating and verifying
information, processing and maintaining information, and disclosing and
providing information; to train personnel and to be able to respond to
a collection of information; to search data sources; to complete and
review the collection of information; and to transmit or otherwise
disclose the information. The total annual burden hours estimated for
this ICR are summarized in the table below.
[[Page 79348]]
Total Estimated Annualized Burden--Hours
----------------------------------------------------------------------------------------------------------------
Average
Number of Number of Total burden per Total burden
Form name respondents responses per responses response (in hours
respondent hours)
----------------------------------------------------------------------------------------------------------------
Form 1: Demographic, Service 56 1 56 425 23,800
Utilization, and Clinical
Indicators Data................
Form 2: Performance and System 56 1 56 425 23,800
Outcome Benchmark Data.........
-------------------------------------------------------------------------------
Total....................... 56 .............. 56 .............. 47,600
----------------------------------------------------------------------------------------------------------------
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015-31936 Filed 12-18-15; 8:45 am]
BILLING CODE 4165-15-P
